293 related articles for article (PubMed ID: 24096380)
41. Alloreactive natural killer cells in hematopoietic stem cell transplantation.
Pegram HJ; Ritchie DS; Smyth MJ; Wiernik A; Prince HM; Darcy PK; Kershaw MH
Leuk Res; 2011 Jan; 35(1):14-21. PubMed ID: 20719383
[TBL] [Abstract][Full Text] [Related]
42. Human natural killer cells: origin, receptors, function, and clinical applications.
Moretta L; Montaldo E; Vacca P; Del Zotto G; Moretta F; Merli P; Locatelli F; Mingari MC
Int Arch Allergy Immunol; 2014; 164(4):253-64. PubMed ID: 25323661
[TBL] [Abstract][Full Text] [Related]
43. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
44. [Graft versus host disease and cytokines].
Itoh T
Nihon Rinsho; 2003 Sep; 61(9):1504-11. PubMed ID: 14515716
[TBL] [Abstract][Full Text] [Related]
45. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
46. Human NK cells: from HLA class I-specific killer Ig-like receptors to the therapy of acute leukemias.
Moretta A; Locatelli F; Moretta L
Immunol Rev; 2008 Aug; 224():58-69. PubMed ID: 18759920
[TBL] [Abstract][Full Text] [Related]
47. Experimental evidence of interleukin-2 activity in bone marrow transplantation.
Mazumder A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S37-42. PubMed ID: 9457392
[TBL] [Abstract][Full Text] [Related]
48. Human NK receptors: from the molecules to the therapy of high risk leukemias.
Moretta L; Locatelli F; Pende D; Sivori S; Falco M; Bottino C; Mingari MC; Moretta A
FEBS Lett; 2011 Jun; 585(11):1563-7. PubMed ID: 21554879
[TBL] [Abstract][Full Text] [Related]
49. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children.
Mochizuki K; Kikuta A; Ito M; Sano H; Akaihata M; Kobayashi S; Ohto H; Hosoya M
Clin Transplant; 2011; 25(6):892-7. PubMed ID: 21070366
[TBL] [Abstract][Full Text] [Related]
50. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
51. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
André-Schmutz I; Dal Cortivo L; Fischer A; Cavazzana-Calvo M
Cytotherapy; 2005; 7(2):102-8. PubMed ID: 16040389
[TBL] [Abstract][Full Text] [Related]
52. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients.
Huang XJ
Best Pract Res Clin Haematol; 2011 Sep; 24(3):351-8. PubMed ID: 21925088
[TBL] [Abstract][Full Text] [Related]
53. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
54. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self.
Ruggeri L; Aversa F; Martelli MF; Velardi A
Immunol Rev; 2006 Dec; 214():202-18. PubMed ID: 17100886
[TBL] [Abstract][Full Text] [Related]
55. Will post-transplantation cell therapies for pediatric patients become standard of care?
Lankester AC; Locatelli F; Bader P; Rettinger E; Egeler M; Katewa S; Pulsipher MA; Nierkens S; Schultz K; Handgretinger R; Grupp SA; Boelens JJ; Bollard CM;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):402-11. PubMed ID: 25064748
[TBL] [Abstract][Full Text] [Related]
56. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
57. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
Owaidah TM
Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
[TBL] [Abstract][Full Text] [Related]
58. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
Slavin S
Acta Haematol; 2005; 114(4):214-20. PubMed ID: 16269861
[TBL] [Abstract][Full Text] [Related]
59. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
Chang YJ; Huang XJ
Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
[TBL] [Abstract][Full Text] [Related]
60. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
